Navigation Links
PDI Reports 2009 Second Quarter Financial Results
Date:8/5/2009

SADDLE RIVER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII), a leading provider of sales and marketing support to U.S. pharmaceutical companies, today reported financial and operational results for the second quarter ended June 30, 2009. Recent highlights include:

  • Four new business wins expected to exceed $18 million in revenue over 12 months
  • Signed agreement with The Medical Affairs Company (TMAC(R)) to enhance our service offerings
  • Facilities realignment and continued cost reductions
  • Mutual termination of product commercialization contract
  • Appointment of current director Gerald P. Belle to the newly-established position of lead independent director

Commenting on today's announcement, Nancy Lurker, Chief Executive Officer of PDI, Inc., stated, "While we recognize that the first half of the year has been difficult, with operating losses of $4.7 million and $10.3 million for the second quarter and first six months, respectively, we are working diligently to improve the Company's financial position and are optimistic that these efforts will pay off. Thus far in 2009, we have implemented a number of initiatives to advance PDI to a more solid competitive stance, including leveraging and expanding our core CSO capabilities, strategically adding to management, reducing expenses and taking appropriate charges in order to better structure the Company for future success. We are confident that adherence to this strategy will put us on a trajectory toward profitability as we strategically align the business units to be profitable while adding new, high quality personnel with the experience and drive to build our business.

"Notably, during the quarter we announced
'/>"/>

SOURCE PDI, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. NxStage Reports Second Quarter 2009 Financial Results
4. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
5. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
6. CuraGen Reports Second Quarter 2009 Financial Results
7. ERT Reports Second Quarter 2009 Results
8. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
9. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
10. Caliper Life Sciences Reports Second Quarter 2009 Results
11. Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 The North American chromatography systems ... from 2014 to 2019. Based on geography, this market has ... and Mexico . The U.S. accounted for ... . The major factors driving the growth of chromatography systems ... industries are the prime users of chromatography techniques. ...
(Date:4/21/2015)... WORTH, Texas , April 21, 2015 ... to grow from $313.0 million in 2014 to $605.1 million ... period under consideration. Browse through the TOC ... for an in-depth analysis of the industry trends and ... http://www.micromarketmonitor.com/market/north-america-bio-stimulants-6850160039.html Early buyers ...
(Date:4/21/2015)... , April 21, 2015  Scientists from the ... research organization, published a paper today outlining new ... microalgae called diatoms. The researchers, led by first ... author Philip Weyman , Ph.D., conclude that ... understanding of diatom genetics and thus facilitate advances ...
(Date:4/21/2015)... Invetech , a global leader ... contract manufacturing, and  NanoCellect Biomedical, a company ... sorting technology for life science researchers, today announced ... platform. Headquartered in San ... microchip-based cell sorting technology. NanoCellect,s flow cytometry platform ...
Breaking Biology Technology:North American Chromatography systems Market by Types, & by End-Users - Forecast to 2019 2North American Chromatography systems Market by Types, & by End-Users - Forecast to 2019 3North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3
... New York on Monday, September 10th, SAN ... biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... President and Chief Executive Officer, will present at,the ... p.m. Eastern,time on Monday, September 10, 2007. The ...
... CDC to Ensure US,s Preparedness ... Emergency, CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September ... company, announced today that the US Food and ... Vaccine, Live) vaccine,for protection against smallpox. The vaccine ...
... announced,today that one year findings from the ... net clinical benefit for patients with acute,ST-segment ... Heparin (UFH). The ExTRACT-TIMI 25 and ... sessions at the European Society of Cardiology ...
Cached Biology Technology:FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 2FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 3FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 5New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... 1, 2015   Medisafe ™, the leading global ... iOS and Android smartphones and ... into the platform to allow patients to track and ... first time, patients will be able to visualize in ... important biometrics, such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... weapon in the arsenal against cancer: Nanoparticles that identify, ... cells alone. Led by Carl Batt, the Liberty ... nanoparticles shaped something like a dumbbell made ... They then attached antibodies, which target a molecule found ...
... of God and the nature of religion, two distinguished ... in evolutionary biology with a focus on brain science, ... Tiger and pioneering neuroscientist Michael McGuire elucidate perennial questions ... arise? What is its source? And why does every ...
... breakthrough treatments for the most common cancers could soon come ... At the ESMO Conference on Sarcoma and GIST, to ... 2010, researchers and some of the world,s leading experts will ... found in muscle, blood vessels, deep skin tissues, nerves and ...
Cached Biology News:Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Which came first: Religion or the brain? 2Spotlight on rare tumors in hunt for new cancer treatments 2
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
LabFax: Immunochemistry...
Biology Products: